Friday, April 25, 2025 4/25/2025

Specificity and Molecular Definition of Pathogenic Lymphocytes in Sjogren's Syndrome

Award Number: R01AR074310
ORGANIZATION: NATIONAL INSTITUTE OF ARTHRITIS & MUSCULOSKELETAL & SKIN DISEASES
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

Group Awards By:

View Award Description

Specificity and Molecular Definition of Pathogenic Lymphocytes in Sjogren's Syndrome - PROJECT SUMMARY Sjögren's syndrome (SS) is a rheumatic autoimmune disease selectively targeting salivary and lacrimal glands, leading to painful dry mouth and eyes, oral infections, severe dental caries/tooth loss, fatigue, arthritis, neurologic involvement, and malignant B cell lymphoma. There are no effective biologic therapies. The strongest genetic risk factor is MHC class II DR3/DQ2. CD4+ T cells dominate salivary gland (SG) focal lymphocytic infiltrates, but B cells are also present. CD4+ T cells drive germinal center formation and class-switched, somatically hyper- mutated antibodies, all characteristic features of SS SG. Identification of the antigens and immunologic pathways driving the aberrant immune responses in SS is the focus of our proposal. In previous work, we isolated paired T cell receptor (TCR) α and β sequences of clonally expanded SG CD4+ T cells from DR3/DQ2+ patients and showed that the degree of clonal expansion correlated with reduced salivary flow and increased SG fibrosis. These are the first findings to link SG T cell infiltrates with low salivary flow and SG damage. Expanded clones within and between patients showed TCR amino acid similarities at sites contacting antigenic peptide, providing evidence that common antigen(s) drive SG CD4+ T cell proliferation. We used SG plasmablast-derived monoclonal antibodies (mAbs) from the same patients to identify 15 new candidate autoantigens. We also identified key transcripts overexpressed in SG CD4+ T cells that are characteristic of T follicular helper (Tfh) cells or may promote Tfh differentiation (TNFSF8-encoded CD30L). This proposal will test three hypotheses: i) previously unidentified antigens are targeted by SG CD4+ T cells and plasmablasts in SS, ii) autoreactivity to novel antigens may explain oral and neurologic manifestations of SS, and iii) clonally expanded SG CD4+ T cells express a unique transcriptional signature that promotes Tfh cell differentiation. Aim 1. Determine whether shared TCRs expressed on clonally expanded SG CD4+ T cells are specific for canonical and novel SS antigens bound by SG plasmablasts of the same subjects and are present in peripheral blood (PB) of SS cases, with frequencies reflecting SG disease features and severity. Aim 2. Identify the specificities of SS salivary gland plasmablast-derived mAbs and determine whether they have functional consequences and/or cross react with canonical SS antigens. Aim 3. Determine the transcriptional program of SG CD4+ T cells expressing shared, disease-associated TCRs, validate their predicted phenotypes and their localization in SG tissue, and test the hypothesis that CD30/CD30L signaling promotes human Tfh differentiation. This high impact research will identify autoantigens and SG T cell properties that may explain oral and neurologic SS pathology and that may be exploited to eliminate or regulate lymphocytes that drive chronic disease.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2024 ( Subtotal = $0 )
2024	2022	OKLAHOMA MEDICAL RESEARCH FOUNDATION	825 NE 13TH ST	OKLAHOMA CITY	OK	73104	OKLAHOMA	USA	Arthritis, Musculoskeletal and Skin Diseases Research	000	5	8/2/2024	NON-COMPETING CONTINUATION	$0
														Subtotal = $0

Issue Date FY: 2022 ( Subtotal = $520,558 )
2022	2022	OKLAHOMA MEDICAL RESEARCH FOUNDATION	825 NE 13TH ST	OKLAHOMA CITY	OK	73104	OKLAHOMA	USA	Arthritis, Musculoskeletal and Skin Diseases Research	000	5	6/23/2022	NON-COMPETING CONTINUATION	$520,558
														Subtotal = $520,558

Issue Date FY: 2021 ( Subtotal = $521,813 )
2021	2021	OKLAHOMA MEDICAL RESEARCH FOUNDATION	825 NE 13TH ST	OKLAHOMA CITY	OK	73104	OKLAHOMA	USA	Arthritis, Musculoskeletal and Skin Diseases Research	000	4	8/13/2021	NON-COMPETING CONTINUATION	$521,813
														Subtotal = $521,813

Issue Date FY: 2020 ( Subtotal = $540,620 )
2020	2020	OKLAHOMA MEDICAL RESEARCH FOUNDATION	825 NE 13TH ST	OKLAHOMA CITY	OK	73104	OKLAHOMA	USA	Arthritis, Musculoskeletal and Skin Diseases Research	000	3	8/31/2020	NON-COMPETING CONTINUATION	$540,620
														Subtotal = $540,620

Issue Date FY: 2019 ( Subtotal = $534,514 )
2019	2019	OKLAHOMA MEDICAL RESEARCH FOUNDATION	825 NE 13TH ST	OKLAHOMA CITY	OK	73104	OKLAHOMA	USA	Arthritis, Musculoskeletal and Skin Diseases Research	001	2	7/4/2019	NON-COMPETING CONTINUATION	$534,514
2019	2018	OKLAHOMA MEDICAL RESEARCH FOUNDATION	825 NE 13TH ST	OKLAHOMA CITY	OK	73104	OKLAHOMA	USA	Arthritis, Musculoskeletal and Skin Diseases Research	000	1	3/7/2019	NEW	$0
														Subtotal = $534,514

Issue Date FY: 2018 ( Subtotal = $538,519 )
2018	2018	OKLAHOMA MEDICAL RESEARCH FOUNDATION	825 NE 13TH ST	OKLAHOMA CITY	OK	73104	OKLAHOMA	USA	Arthritis, Musculoskeletal and Skin Diseases Research	000	1	9/7/2018	NEW	$538,519
														Subtotal = $538,519

Grand Total All Awards = $2,656,024

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Specificity and Molecular Definition of Pathogenic Lymphocytes in Sjogren's Syndrome

Award Number: R01AR074310

ORGANIZATION: NATIONAL INSTITUTE OF ARTHRITIS & MUSCULOSKELETAL & SKIN DISEASES

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer